Displaying results 1 - 8 / 8
results / page
What publicationinformation is included in the service?
Publication name
Authors
Publication channel
Year

Longterm prediction of failure after treatment of cervical precancer

Open access
DOI
10.1111/1471-0528.16023
Arbyn, M.; Gondry, J.; Nieminen, P.
Bjog: an international journal of obstetrics and gynaecology2020

T-cell Subset Features and Distributions Evolve Across the Colorectal Precancer-Cancer Spectrum

Peer-reviewed
DOI
10.1158/2326-6066.CIR-25-0481
Takashima, Yasutoshi; Dias Costa, Andressa; Akimoto, Naohiko; Ugai, Tomotaka; Bell, Phoenix; Väyryne...
Cancer immunology research2025

Order of HPV/Chlamydia infections and cervical high-grade precancer risk: A case-cohort study

Peer-reviewed
DOI
10.1002/ijc.28173
Luostarinen, Tapio; Namujju, Proscovia B.; Merikukka, Marko; Dillner, Joakim; Hakulinen, Timo; Koske...
International journal of cancer2013

Incomplete excision of cervical precancer as a predictor of treatment failure:a systematic review and meta-analysis

Peer-reviewed
Open access
DOI
10.1016/S1470-2045(17)30700-3
Arbyn, Marc; Redman, Charles W. E.; Verdoodt, Freija; Kyrgiou, Maria; Tzafetas, Menelaos; Ghaem-Magh...
The Lancet Oncology2017

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: Final event-driven analysis of the randomised, double-blind PATRICIA trial

Peer-reviewed
DOI
10.1128/CVI.00591-14
Apter, Dan; Kitchener, Henry C; Teixeira, Julio C; Jaisamrarn, Unnop; Limson, Gerara; Szarewski, Ann...
Clinical and vaccine immunology2015

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Peer-reviewed
DOI
10.1016/S1470-2045(11)70287-X
Wheeler Cosette M; Castellsagué Xavier; Garland SuzanneM; Szarewski Anne; Paavonen Jorma; Naud Paulo...
The Lancet Oncology2012

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study

Peer-reviewed
DOI
10.1016/j.vaccine.2021.01.074
Joura, Elmar A.; Ulied, Angels; Vandermeulen, Corinne; Rua Figueroa, Milagrosa; Seppä, Ilkka; Hernan...
Vaccine2021

Photon iso-effective dose for cancer treatment with mixed field radiation based on dose-response assessment from human and an animal model:clinical application to boron neutron capture therapy for head and neck cancer

Peer-reviewed
Open access
DOI
10.1088/1361-6560/aa8986
Gonzalez, S. J.; Pozzi, E. C. C.; Hughes, A. Monti; Provenzano, L.; Koivunoro, H.; Carando, D. G.; T...
Physics in medicine and biology2017

Longterm prediction of failure after treatment of cervical precancer

Open access
DOI
10.1111/1471-0528.16023
2020

T-cell Subset Features and Distributions Evolve Across the Colorectal Precancer-Cancer Spectrum

Peer-reviewed
DOI
10.1158/2326-6066.CIR-25-0481
2025

Order of HPV/Chlamydia infections and cervical high-grade precancer risk: A case-cohort study

Peer-reviewed
DOI
10.1002/ijc.28173
2013

Incomplete excision of cervical precancer as a predictor of treatment failure:a systematic review and meta-analysis

Peer-reviewed
Open access
DOI
10.1016/S1470-2045(17)30700-3
2017

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: Final event-driven analysis of the randomised, double-blind PATRICIA trial

Peer-reviewed
DOI
10.1128/CVI.00591-14
2015

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Peer-reviewed
DOI
10.1016/S1470-2045(11)70287-X
2012

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study

Peer-reviewed
DOI
10.1016/j.vaccine.2021.01.074
2021

Photon iso-effective dose for cancer treatment with mixed field radiation based on dose-response assessment from human and an animal model:clinical application to boron neutron capture therapy for head and neck cancer

Peer-reviewed
Open access
DOI
10.1088/1361-6560/aa8986
2017